In the last “one page to access” we addressed the growth of Latin America in relation to the Global market and the various opportunities that the Brazilian market presents for the rare disease and high complexity segment.
In this issue, continuing the theme, we will delve a little deeper into the numbers referring to the market of “non-retail” market.
According to insights provided by IQVIA, demand for pharmaceutical drug volumes in Latin America has been recovering since 2021 after a significant decline in the non retail drug channel during 2020.
This recovery occurries in virtually all Latin American countries, in terms of volume and spending, and non-retail channel, volume and value recovery has been driven by patients returning to diagnosis and treatment.
In addition to the econimic upturn of the market, another important point to highlight is that, in the last decade, healthcare budget has increased in most Latin American countries:
The increase in health financing in most Latin American countries strengthens health services, generating conditions of social protection and improving conditions of access to medicine for their populations.
In Brazil, besides the numbers that highlight the upturn of non-retail market, the senate has already approved the proposal that makes it compulsory to notify rare disease diagnoses to the country’s health authorities, seeking to improve the collection of epidemiological data and facilitate the purchase of specific medicines by the Single Health System.
The relevance of the topic regarding rare diseases has an increasing proportion in the country. A Brazilian project under analysis seeks to expand the list of diseases detected free of charge by the Guthrie Test in newborns to provide early diagnosis of more than 50 diseases, accelerating the diagnosis and access to treatment in Brazil.
The proposal that gives tax benefits to taxpayers with a dependent who has a rare disease is under discussion.
For Multicare, enabling access to life-saving medicines can make the future possible for millions of people.
We are the best option for access to medicines for the treatment of rare or highly complex diseases. We have been present in the pharmaceutical market for 37 years and have become a reference in the area of rare and highly complex diseases in the last decade.
Talk to us: firstname.lastname@example.org
Learn more: www.multicarepharma.com